Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Malaria science advances amid eradication pessimism
Fri August 23rd - British scientists have unveiled major discoveries about malaria – as the World Health Organisation warned the disease would not be eradicated in the near future. More
Polypill success at preventing cardiovascular diseases
Fri August 23rd - A low-cost polypill, which combines four cardiovascular drugs into a single pill, has cut the risk of major cardiovascular events in the first trial of its kind, researchers report today. More
Half hour daily activity backed in new analysis
Fri August 23rd - People who undertake daily physical activity, regardless of intensity, may gain the optimal health benefits, researchers have reported. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

Abandoned diabetes drug shows lymphoma promise

Thursday April 18th, 2019

A drug abandoned as a treatment for diabetes may protect against the development of T-cell lymphoma, Scottish researchers have reported.

The Dundee University research at first centred on metformin – but then switched to phenformin.

The drug was abandoned in many countries 30 years ago after patients developed fatal lactic acidosis.

The latest research, published in Cell Reports, involved a laboratory mouse model and centred on a protein AMPK, which was thought to confer protection against the disease.

The laboratory studies showed that AMPK played a key role in protecting against lymphoma development. Metformin activates AMPK but the researchers found the drug could not penetrate diseases cells. Phenformin was able to do this.

Other studies have linked metformin to protection against the cancer.

Researcher Professor Grahame Hardie said: “We now think that the apparent protective effect of metformin in humans was due to activation of AMPK not in the cancer cells themselves, but elsewhere in the body, which protects against cancer indirectly by lowering insulin levels.

"On the other hand, the protective effect of phenformin is due to activation of AMPK within the cells that give rise to the cancer, a mechanism that is likely to be applicable to other forms of cancer.”

He added: “If our findings can be applied to humans, individuals at high risk of developing cancer might be treated with phenformin.

"The small risk of lactic acidosis caused phenformin to be dropped for use in diabetes - but may be more acceptable if it was used as an anti-cancer agent.”

Cell Reports 16 April 2019

Tags: Cancer | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)